Two Sigma Investments LP Cuts Stock Holdings in Ikena Oncology, Inc. (NASDAQ:IKNA)

Two Sigma Investments LP lowered its position in Ikena Oncology, Inc. (NASDAQ:IKNA) by 35.7% in the fourth quarter, Holdings Channel reports. The fund owned 100,778 shares of the company’s stock after selling 55,935 shares during the period. Two Sigma Investments LP’s holdings in Ikena Oncology were worth $165,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BML Capital Management LLC lifted its position in shares of Ikena Oncology by 395.8% during the 4th quarter. BML Capital Management LLC now owns 3,585,866 shares of the company’s stock worth $5,881,000 after buying an additional 2,862,578 shares during the last quarter. Gilead Sciences Inc. acquired a new position in Ikena Oncology in the 4th quarter valued at about $3,294,000. Peapod Lane Capital LLC purchased a new stake in shares of Ikena Oncology during the fourth quarter worth approximately $833,000. JPMorgan Chase & Co. boosted its holdings in shares of Ikena Oncology by 18,244.1% in the fourth quarter. JPMorgan Chase & Co. now owns 155,741 shares of the company’s stock valued at $255,000 after acquiring an additional 154,892 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Ikena Oncology by 21.0% during the 4th quarter. Geode Capital Management LLC now owns 327,962 shares of the company’s stock worth $538,000 after purchasing an additional 56,936 shares during the period. Institutional investors and hedge funds own 75.00% of the company’s stock.

Ikena Oncology Stock Performance

NASDAQ:IKNA opened at $1.37 on Friday. The stock has a fifty day moving average price of $1.19 and a two-hundred day moving average price of $1.38. The stock has a market capitalization of $66.11 million, a price-to-earnings ratio of -1.11 and a beta of 0.45. Ikena Oncology, Inc. has a 1 year low of $0.97 and a 1 year high of $1.94.

Ikena Oncology (NASDAQ:IKNA) last posted its earnings results on Thursday, May 8th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03. On average, analysts predict that Ikena Oncology, Inc. will post -0.91 EPS for the current year.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.